Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT101-5 in Subjects With Early Parkinson's Disease
NCT06175767Phase 2Not yet recruiting
- Sponsor
- Mthera Pharma
- Start
- Sep 2027
- Primary completion
- Jan 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of MT101-5 in Parkinson's disease (PD), sponsored by Mthera Pharma. Planned start Sep 2027; status: not yet recruiting.
02
Drugs
MT101-5
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06175767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06175767.